Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition

References

• Dummer R, Zucca E. Cutaneous T-cell lymphoma: from genetics to clinical practice. Oncology (Williston Park) 2007;21(Suppl. 1):7–8.
   PubMedGoogle Scholar
• Willemze R, Jaffe ES, Burg G, . WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768–3785.
   PubMed Web of Science ®Google Scholar
• Dummer R. Primary cutaneous lymphomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2007;18(Suppl. 2):ii61–ii62.
   PubMedGoogle Scholar
• Farol LT, Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Ther 2004;4:180–188.
   PubMedGoogle Scholar
• Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1:181–193.
   PubMed Web of Science ®Google Scholar
• US FDA Targretin. US Targretin® Package Insert. 2010.
   Google Scholar
• EMEA Targretin. EMEA Targretin® Package Leaflet. 2010.
   Google Scholar
• Duvic M, Hymes K, Heald P, . Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456–2471.
   PubMed Web of Science ®Google Scholar
• Duvic M, Martin AG, Kim Y, . Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581–593.
   PubMed Web of Science ®Google Scholar
• Germain P, Chambon P, Eichele G, . International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006;58:760–772.
   PubMed Web of Science ®Google Scholar
• Mangelsdorf DJ, Kliewer SA, Kakizuka A, . Retinoid receptors. Recent Prog Horm Res 1993;48:99–121.
   PubMedGoogle Scholar
• Assaf C, Bagot M, Dummer R, . Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006;155:261–266.
   PubMed Web of Science ®Google Scholar
• Duvic M, Edelson R. Cutaneous T-cell lymphoma. J Am Acad Dermatol 2004;51:S43–S45.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, . Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25: 3109–3115.
   PubMed Web of Science ®Google Scholar
• Duvic M, Olsen EA, Breneman D, . Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2009;9:412–416.
   PubMedGoogle Scholar
• US FDA Zolinza. US Zolinza® Package Insert. 2010.
   Google Scholar
• Nielsen M, Nissen MH, Gerwien J, . Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3. Blood 2002;99:973–977.
   PubMed Web of Science ®Google Scholar
• Fantin VR, Loboda A, Paweletz CP, . Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008;68: 3785–3794.
   PubMed Web of Science ®Google Scholar
• Sommer VH, Clemmensen OJ, Nielsen O, . In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 2004;18:1288–1295.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, . Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31–39.
   PubMed Web of Science ®Google Scholar
• Rascle A, Johnston JA, Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol 2003;23:4162–4173.
   PubMed Web of Science ®Google Scholar
• Epping MT, Wang L, Plumb JA, . A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci USA 2007;104:17777–17782.
   PubMed Web of Science ®Google Scholar
• Ferrara FF, Fazi F, Bianchini A, . Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 2001;61:2–7.
   PubMed Web of Science ®Google Scholar
• Zhang C, Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Ther 2006;19:264–271.
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074–1080.
   PubMed Web of Science ®Google Scholar
• Luger K, Mader AW, Richmond RK, . Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997;389:251–260.
   PubMed Web of Science ®Google Scholar
• Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, part I: Covalent histone modifications. Trends Mol Med 2007;13:363–372.
   PubMed Web of Science ®Google Scholar
• Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 2002;86:41–65.
   PubMed Web of Science ®Google Scholar
• McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321–344.
   PubMed Web of Science ®Google Scholar
• He LZ, Tolentino T, Grayson P, . Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001;108:1321–1330.
   PubMed Web of Science ®Google Scholar
• Cella DF, Tulsky DS, Gray G, . The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570–579.
   PubMed Web of Science ®Google Scholar
• Chren MM, Lasek RJ, Sahay AP, . Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001;5:105–110.
   PubMed Web of Science ®Google Scholar
• Gootenberg JE, Ruscetti FW, Mier JW, . Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med 1981;154:1403–1418.
   PubMed Web of Science ®Google Scholar
• Whang YM, Choi EJ, Seo JH, . Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor beta expression in head and neck squamous carcinoma (HNSCC) cells. Cancer Chemother Pharmacol 2005;56: 543–555.
   PubMed Web of Science ®Google Scholar
• Johnson BS, Chandraratna RA, Heyman RA, . Retinoid X receptor (RXR) agonist-induced activation of dominant-negative RXR-retinoic acid receptor alpha403 heterodimers is developmentally regulated during myeloid differentiation. Mol Cell Biol 1999;19: 3372–3382.
   PubMed Web of Science ®Google Scholar
• De Los SM, Zambrano A, Sanchez-Pacheco A, . Histone deacetylase inhibitors regulate retinoic acid receptor beta expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms. Mol Endocrinol 2007;21:2416–2426.
   PubMed Web of Science ®Google Scholar
• Touma SE, Goldberg JS, Moench P, . Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clin Cancer Res 2005;11:3558–3566.
   PubMed Web of Science ®Google Scholar
• Xu XC. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett 2007;253:14–24.
   PubMed Web of Science ®Google Scholar
• Hewson QC, Lovat PE, Pearson AD, . Retinoid signalling and gene expression in neuroblastoma cells: RXR agonist and antagonist effects on CRABP-II and RARbeta expression. J Cell Biochem 2002;87:284–291.
   PubMed Web of Science ®Google Scholar
• Schug TT, Berry DC, Shaw NS, . Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007;129:723–733.
   PubMed Web of Science ®Google Scholar
• Zhang C, Hazarika P, Ni X, . Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234–1240.
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 1999;10:215–225.
   PubMed Web of Science ®Google Scholar
• Matsuoka H, Fujimura T, Hayashi M, . Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem Pharmacol 2007;74:465–476.
   PubMed Web of Science ®Google Scholar
• Zhang C, Richon V, Ni X, . Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005;125:1045–1052.
   PubMed Web of Science ®Google Scholar
• Nieto-Rementeria N, Perez-Yarza G, Boyano MD, . Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol 2009;160:519–526.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kato H, Kobayashi Y, . Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 2010;101:196–200.
   PubMed Web of Science ®Google Scholar
• Steinhoff M, Beyer M, Roewert-Huber J, . Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. J Am Acad Dermatol 2008;58:88–91.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang H, Bueso-Ramos C, . Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111:1060–1066.
   PubMed Web of Science ®Google Scholar
• Kelly WK, O'Connor OA, Krug LM, . Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923–3931.
   PubMed Web of Science ®Google Scholar
• Smit JV, Franssen ME, de Jong EM, . A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J Am Acad Dermatol 2004;51:249–256.
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Heaney ML, Schwartz L, . Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24:166–173.
   PubMed Web of Science ®Google Scholar